Top Industry Leaders in the Pulmonary Edema Market
Latest Pulmonary Edema Companies Updates:
April 2023: ResMed acquired Propeller Health, a leader in digital health solutions for respiratory diseases, including pulmonary edema. This move strengthens ResMed's portfolio in remote patient monitoring and data-driven care management.
March 2023: AstraZeneca entered into a collaboration with BioNTech to develop novel immune-oncology therapies for various disease indications, including pulmonary edema associated with lung cancer.
November 2023: Novartis received FDA approval for Entresto (sacubitril/valsartan) for the treatment of heart failure with preserved ejection fraction (HFpEF), a condition that can lead to
pulmonary edema. This approval expands the potential patient base for Entresto.
September 2023: Verve Therapeutics announced the first patient dosed in a Phase 1b clinical trial for VERVE-101, a potential gene therapy for the treatment of pulmonary edema associated with pulmonary arterial hypertension.
List of Pulmonary Edema Key companies in the market:
- Pfizer Inc. (U.S.)
- ARGON MEDICAL (U.S.)
- Edwards Lifesciences Corporation (U.S.)
- BD (U.S.)
- Alcaliber S.A. (Spain)
- Lupin Pharmaceuticals, Inc. (India)
- Vitaltec Corporation (China)
- Medtronic (U.S.)
- Koninklijke Philips N.V. (The Netherlands)
- Siemens Healthcare GmbH (Germany)
